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INTRODUCTION 
The aim of this Thesis is to elucidate a better understanding of the financial burdens that 
patients with chronic blood cancers face in paying for life-saving treatments. Many people are aware of 
the burden cancer places on an individual and may have personal experience with a family member or 
friend being diagnosed with the disease. Most citizens and policymakers are also living in a time of 
hyper-awareness of the growing issue of unsustainable drug prices in the United States. However, the 
majority of previous research and policies address societal level burdens of rising healthcare costs, 
rather than individual financial burdens. The rising societal-level costs to treat cancer and the 
introduction of novel prescription drug therapies, are having an even further adverse effect on an 
individual basis. There must be further investigation and exposure on how subjective financial burden 
affects individual cancer patients’ health and quality of life.  
The specific questions I seek to answer through this Thesis are: 
1. What factors are associated with financial difficulty among cancer patients? 
2. How do these factors vary for people with cancer drugs, versus those who use other 
courses of treatment? 
3. Among cancer drug users, what kinds of cost coping strategies do patients employ? 
4. How do these strategies vary between cancer and non-cancer drugs? 
5. How are mental and physical health-related quality of life related to financial burden in 
cancer patients? 
6. Is quality of life different for patients with and without cancer drug use? 
 I will begin by shedding light on how we reached this point in the United States by taking a 
macro view of historical drug-pricing related policies and focusing specifically on the current high price 
of life-saving oral-targeted cancer therapies. Additionally, I will provide background information on the 
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disease characteristics of chronic blood cancers to illustrate why the use of oral drugs is such a novel and 
important therapy.  Once it is explained why patients are facing high cost-sharing responsibilities, I will 
delve into the negative consequences these patients face as a result of not being able to afford life-
saving medications. These include not adhering to treatment regiments (i.e. “cost-related non-adherent 
behaviors”), cost-defraying techniques (i.e. what sacrifices patients make in order to pay for 
medication), and finally the consequences of having poorer mental and physical health outcomes also 
defined as “financial toxicity”.  
Using a survey distributed by Patient Power, an online support community for patients with 
cancer, data was collected on a variety of topics including sociodemographic characteristics, subjective 
financial burden, treatment behaviors and subjective quality of life. A total of 239 patients with either 
chronic lymphocytic leukemia or multiple myeloma responded for analysis. 
Receiving a cancer diagnosis is a major, life-altering event with a proven impact on health-
related quality of life alone and social identify (Park, 2009). Findings from this study support the notion 
that patients should not have suffer from the additional financial burdens of treatment due to the 
unaffordable costs. Intervention strategies for financial toxicity and policy initiatives at lowering costs 
for oral anticancer drugs are urgently needed.  
BACKGROUND & LITERATURE REVIEW 
The High Cost of Prescription Drugs in the United States  
Total health expenditures in the United States have increased substantially over the past several 
decades. Additionally, the U.S. has higher prices for most health care services and prescription drugs, 
according to available internationally comparable data (Kamal and Cox, 2018). From the early 2000’s to 
around 2010, overall prescription drug expenditure was at a modest, but insignificant, and unalarming 
growth rate (Kamal and Cox, 2018). With the introduction of Medicare Part D in 2010 and the Affordable 
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Care Act in 2012, prescription drug spending actually decreased. However, seen in Figure 1 prescription 
drug spending began rising sharply in 2014, at over an 11% growth rate. This growth is attributed to the 
expenditures on specialty drugs, including medications to treat cancer and hepatitis C (Kamal and Cox, 
2018). Furthermore, Medicare’s spending on prescription drugs, despite the introduction of Part D, 
continues to rise. For example, from 2004 to 2014, Medicare’s share of drug expenditures increased 
form 2% of $193 billion to 29% of $298 billion (Kamal and Cox, 2018). Since 2014, the trend in both 
medical and drug expenditures continues to rise at an unsustainable rate.  
A way to measure spending trends is to see what percentage of the economy is devoted to 
health and healthcare spending. Figure 2 illustrates the percentages that the U.S. spends out of its Gross 
Domestic Product (GDP) on health. In 1970, the U.S. only spent around 7% of its GDP on total health 
spending, both through public and private funds. By 2017, the amount has increased to almost 18% of 
GDP (Kamal and Cox, 2018). 
Additionally, the U.S. is an outlier to the rest of the world on how much it spends out of its GDP 
on health. For example, in 2016, the U.S. spent 18% of its Gross Domestic Product (GDP) on healthcare, 
whereas the next highest country only spent 12%. The average amount spent on healthcare per person 
in comparable countries ($5,198) is half that of the U.S. ($10,348) (Kamal and Cox, 2018). Meanwhile, 
utilization of these services, including physician consultations and hospital stays, is lower than in many 
comparable countries. Despite having fewer office visits and shorter average hospital stays, the U.S. 
overall spends twice as much per person on healthcare than do comparable countries (Kamal, 2018). 
The high cost of cancer drugs fits into a larger trend of high medical costs in the United States.  
Prescription drug prices in the United States have been increasing over the past decade and are 
becoming unsustainable and unaffordable for American patients. According to the Centers for Disease 
Control (CDC), half of all Americans have used at least one prescription drug in the past 30 days (CDC, 
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2017). National trends in prescription drug expenditures and projections published for 2017 summarizes 
"total U.S. prescription sales for the 2016 calendar year at $448.2 billion, a 5.8 percent increase" 
compared with 2015 (Schumock, 2017).  Prescription expenditures in clinics totaled nearly $64 billion, a 
12 percent increase from 2015. Hospital drug spending was almost $35 billion, up 3 percent from 2015 
(NCSL, 2018).  
There is not one specific reason why drug prices have reached unsustainable costs, but rather a 
culmination of factors. These include the discovery of innovative specialty drugs (Kamal and Cox, 2018) 
market exclusivity (Kesselheim, 2016) limited negotiation powers by federal and state agencies, multiple 
middlemen and lack of transparency in pricing (Cubanski and Neuman, 2018). The US is an outlier from 
other countries in part because it does not regulate or negotiate the prices of new prescription drugs 
when they come onto the market. Instead, drug makers are allowed to set their own prices for a given 
product and allows every drug that’s proven to be safe come onto the market (Kliff, 2018). There are 
policy trade-offs for not allowing negotiation. One benefit of the US system is that certain drugs that sell 
in the United States may not be available in other countries. Thus, the United States may have the most 
innovative and life-saving treatments.  However, if patients are unable to afford them, the availability of 
innovative treatments could be a moot point (Kliff, 2018). The major dilemma continues to be between 
this trade-off, and policymakers often question – should we exchange innovation for access? Currently, 
we do not have a policy solution to address this question. Science continues to progress with high costs 
of research and development of new drugs, and no limits to the prices that manufacturer’s can set. 
Therefore, innovation may continue to progress, but access may become even more limited as prices 
continue to rise. 
Despite major reforms to our healthcare system in 2010, many critics argue that the Affordable 
Care Act did very little to combat the rising costs of prescription drugs, and prices continue to rise. As an 
explanation for inaction, some point to a deal between President Obama and PhRMA in which Medicare 
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was prohibited from negotiating drug prices in return for PhRMA’s support of the proposed legislation 
(Owens, 2016). Many members of Congress have been outspoken on the issue of high prescription drug 
prices. Bernie Sanders, for example, has his own six-point plan – called the “Sanders Plan” – aimed at 
cutting costs (Sanders, 2018). Individual states are also playing a role in the push for reform; the 
Maryland state legislature recently introduced a bill that would allow a commission to set maximum 
amounts pharmacies and state programs could pay for expensive, brand-name prescriptions (Hicks, 
2018). President Trump himself has called for reforms that would reduce the cost of prescription drugs. 
In his State of the Union address in January 2018, he called bringing drug prices down “one of his 
greatest priorities” (Managan, 2018).  
A new budget deal signed by President Trump in February 2018 included a provision aimed at 
reducing overall prescription drug costs in the United States. The plan requires pharmaceutical 
companies to give Medicare steeper discounts on expensive prescription drugs and includes a five-state 
pilot project that would allow states to negotiate drug prices. While experts predict that the plan could 
make a significant difference for Medicare patients that take very expensive drugs, critics argue that the 
changes will barely make a dent in the issue and do little to address the root causes of high prescription 
drug prices in the U.S. (Tribble, 2018).   
The Price Tag of Cancer Drugs 
Following national trends, orally prescribed cancer medications are priced significantly higher 
than almost any other prescription drugs in the United States. The median monthly cost for new cancer 
drugs increased from $1,770 in the period between 1995 and 1999 to $10,059 in the period between 
2010 and 2014 (Szabo, 2017). Hence, a year’s supply of new cancer drugs is commonly priced at over 
$100,000 and some new drugs even top $250,000 per year (Szabo, 2017).  
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In a global context, the U.S. is an outlier with respect to the costs of cancer drugs around the 
world (Bollycky, 2013). Seen in Figure 3, the median monthly price of 23 cancer drugs in the U.S. is 
$8,700; the same drugs cost $2,600 in the UK, $2,700 in Australia, and $3,200 in China (Crow, 2016) 
Gleevec, a drug used to treat leukemia and other cancers, costs $70,000 per year in the U.S. but only 
$2,500 in India.  
For cancer drugs specifically, the introduction of targeted oral therapies, the monopoly market, 
and the inelastic nature all contribute to high prices. Targeted cancer drugs are for a smaller subset of 
cancer patients and cost more to develop, test, and bring to the market. With the introduction of 
targeted cancer drugs, cheaper one-size-fits-all options are no longer the most effective type of drug. 
Therefore, the price of cancer drugs has risen with the advent of targeted oral therapies (Precision 
Medicine, 2017). Second, there is a monopoly market for cancer drugs. With over the counter 
medication, a patient can pick and choose between brands, causing different brand medications to 
compete for prices. However, with cancer drugs, a virtual monopoly is created because each is 
administered sequentially or in combination. Therefore, it is difficult to pick and choose between 
brands, allowing pharmaceutical companies to charge a higher price (Rajkumar and Siddiqui, 2018). 
Finally, cancer drugs are incredibly inelastic, meaning their demand is insensitive to a change in price. 
Patients and insurers are willing to pay high prices for even a modest improvement in outcome because 
of their life-saving abilities (Rajkumar and Siddiqui, 2018). 
If patients did not have to rely on these cancer drugs as part of treatment, or if the demand was 
low and price was elastic based on the market, cost would not be an issue or potential barrier to care. 
Understanding the life-saving abilities and inelastic demand of cancer drugs requires understanding the 
disease itself, such as the patient population characteristics, disease characteristics, usual courses of 
diagnosis and prognosis, and other possible treatment options for patients with chronic blood cancers.  
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Chronic Blood Cancer Disease Characteristics & Treatments 
Chronic lymphocytic leukemia (CLL) 
CLL is the most common leukemia in adults and is a specific type of cancer of the blood and 
bone marrow, which is the spongy tissue inside bones where blood cells are made (Mayo Clinic, 2018). 
This type of blood cancer is considered “chronic” due to the fact that it typically progresses more slowly, 
than other “acute” forms of cancers (faster onset and disease progression) (Mayo Clinic, 2018). Medical 
professionals have not been able to identify the “trigger” or cause that starts the process of cell 
multiplication and production of abnormal, and ineffective lymphocytes (Mayo Clinic, 2018). Risk factors 
that have been identified by researchers for developing CLL include: age, race, family history and 
exposure to chemicals. On average, people diagnosed with CLL are in their 70’s, and whites are more 
likely to develop CLL than other races (Mayo Clinic, 2018). CLL is diagnosed in different stages, typically 
early, intermediate or advanced. The stage of the cancer determines the treatment route. In general, 
patients diagnosed within the early stage do not require immediate treatment but may later on. 
Treatment types are also based on associated symptoms, overall health and preferences. Treatment 
options in the later or advanced stages include: chemotherapy, immunotherapy, bone marrow 
transplant, and our treatment of interest within this paper – targeted drug therapy.  
In targeted therapies, prescription drugs are used to specifically target the changes inside cells 
that cause them to become cancerous. Unlike standard chemotherapy which are used to attack all cells, 
these drugs attack the more specific CLL cells, without damaging health cells. Oral drugs usually 
prescribed for CLL include Imbruvica (ibrutinib), Venclexta (venetoclax) and Zydelig (idelalisib) (Chronic 
Lymphocytic Leukemia, 2018).  
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Multiple myeloma (MM) 
Multiple myeloma (MM) is also a cancer of bone marrow, but specifically within plasma cells 
(rather than lymphocytes like in CLL) (Multiple Myeloma, 2018). When plasma cells become cancerous 
and grow uncontrollably, they crowd out the healthy blood cells. Treatment discourses are similar to 
CLL, in that it is dependent on the severity and prognosis of the disease when it is diagnosed.  Risk 
factors that have been identified by researchers for developing multiple myeloma include: age, sex, race 
and family history. Most people are diagnosed in their mid-60’s, and risk increases with age. Men are 
more likely to develop multiple myeloma than women, and African American’s are about twice as likely 
to develop the disease than white people (in contrast to CLL). Standard treatments for multiple 
myeloma include chemotherapy, corticosteroids, bone marrow transplant, radiation therapy, and out 
treatment of interested – targeted drug therapy. Oral drugs usually prescribed for multiple myeloma 
include Thalomid (thalidomide), Revlimid (lenalidomide), Pomalyst (pomalidomide), Velcade 
(bortezomib), Farydak (Panobinostat) and Nilarno (ixazomib) (Mayo Clinic, 2018).   
Previously, these cancers had no cure and were treated with courses of surgery cell 
transplantation, chemotherapy, radiation and other more invasive measures as the only option. Oral 
drugs to fight cancer, also known as “TKI inhibitors”, were discovered as a novel and lifesaving 
treatment and are considered by some to be the most successful class of therapies developed in cancer 
(Zafar, 2015). Prior to the use of oral-targeted therapies, median survival of those with blood cancers 
was only 5 to 6 years. Research has shown that maintenance therapy (the ongoing use of targeted 
drugs) increases patient survival rates for blood cancers (Mayo Clinic, 2018). However, survival rates are 
dependent upon stage of cancer when it is diagnosed and can vary from patient to patient.  
Although much less invasive and more effective, the price tag of the treatment would influence 
patients having the ability to afford and use these drugs. For example, when imatinib (a TKI inhibitor for 
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chronic myeloid leukemia) was introduced in 2001, is was one of the highest price drugs available, 
costing $30,000 per year, and by 2012 the cost had tripled to $92,000 (Szabo, 2017). 
Cost-Related Non-Adherence & Cost-Defraying Techniques 
The introduction of TKI inhibitors and oral-targeted therapies has greatly increased survival for 
those with chronic blood cancers. However, despite the significant clinical benefits, previous research 
has found that at least 30% of patients are nonadherent in taking TKI inhibitors due to cost-sharing and 
inability to afford the medication, even after prescription drug coverage (Dusetzina, 2013). It is advised 
by medical professionals that patients should not skip doses and take their medications as prescribed to 
get the best response. Poor adherence to medications is the main reason for inadequate response and 
poor health outcomes, thus stressing the importance of adhering to treatment regiments (Leukemia and 
Lymphoma Society, 2018). 
 This exorbitantly high price of cancer drugs has adverse effects, causing patients to skip 
treatments and experience financial turmoil. Previous research has coined this term “cost-related non-
adherence” (CRN), which refers to individuals who report restricting use of prescription medication 
because of cost. Examples of CRN practices include skipping medications, cutting medication doses in 
half, delaying filling a prescription, using alternative therapies, etc.  It has been shown that individuals 
who report CRN have significantly worse health outcomes (Noens, 2009). 
Many studies have evaluated CRN in different subsets of the patient population and for 
different cancers. A meta-analysis of studies which examined the associations between prescription 
drug plan cost-containment measures found that increased cost sharing (i.e. patients taking more of the 
burden of the payments for medications) is associated with worse adherence among existing users, and 
more frequent discontinuation of previously prescribed therapies (Goldman, 2007). In another example, 
one study found that among patients with breast cancer, higher co-payments were associated with 
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higher rates of non-adherence (Neuget, 2011) Another study found that insurance plans which required 
high cost sharing of oral chemotherapy drugs are associated with a higher risk of prescription 
abandonment (Streeter, 2011). However, given the exclusively high prices, disease onset and 
progression, as well as the critical importance of prescription medications in managing chronic blood 
cancers, the extent to which CRN effects health outcomes and experience other barriers in this 
population needs further studying.  
Financial Toxicity & Health-Related Quality of Life 
A growing body of evidence has coined a new term – “Financial Toxicity” – in relation to the high 
out-of-pocket costs and cost-sharing insinuated on cancer patients. This term is primarily used in 
oncology research and practice to describe the distress of paying for treatments and the impacts on 
quality of life and healthcare. Financial toxicity has even gone as far as to compare to actual biological 
treatment toxicities such as nausea, vomiting, insomnia or depression. These toxicities can lead to 
poorer patient outcomes at times of treatment delays or discontinuation (Gordon, 2017). The current 
literature supports both objective financial burden and subjective financial distress as key markers for 
financial toxicity (Zafar, 2015). However, most research and policies are directed at societal level 
burdens rather than individual financial burdens. The rising costs of healthcare and costs to treat cancer 
on a societal level are also having adverse effects on individuals. This is evident in the fact that even 
insured patients are facing increasing out-of-pocket costs and increased cost-sharing. As insurance 
companies continue to bear the unsustainable growing cost burden of medicine, portions of these costs 
have now shifted to patients more than ever before (Zafar, 2015)  
 Gordon et al. performed a systematic review of literature on financial toxicity among cancer 
survivors in order to identify the determinants and how it is measured (Gordon, 2017). After reviewing 
25 studies, the most commonly reported factors associated with financial toxicity included being female, 
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younger age, lower income, and a more recent diagnosis. The most relevant and important finding to 
add to this discussion is that cancer survivors experienced significantly higher financial toxicity relative 
to non-cancer comparison groups. Ultimately the findings suggest that the financial burdens for cancer 
patients is in excess and can be debilitating to households, quality of life and optimal cancer care 
(Gordon, 2017). Similar studies support this evidence, in particular the financial burdens for blood 
cancer. A study done by Huntington et al. surveyed 100 individuals with ongoing treatment for Multiple 
Myeloma. This group found that 71% had at least minor financial burden and 46% of MM patients used 
savings to pay for treatment.  
 Receiving a diagnosis alone of CLL or MM, aside from financial burden, has been shown to have 
an impact on quality of life and mental health (Zebrack, 2001). Unlike most cancers, the treatment 
discourse of “watch and wait” and long-term survival status can by psychologically difficult for patients 
who know they have a serious health problem. Additionally, because the diagnoses of these two 
diseases tend to occur later in life, patients face these burdens while concurrently coping with other 
health problems due to older age. A study by Shanafelt et al. found that the emotional well-being and 
health related quality of life scores in CLL patients were profoundly lower than those of the general 
population, at all stages of the disease.   
 Ultimately, the previous literature elucidates the dual-threat combination of both receiving a 
cancer diagnosis and high cost-sharing responsibilities of treatment that is potentially leading to 
increased levels of financial toxicity in patients with blood cancers. Oral-targeted therapies have been 
proven to increase life-expectancy in these patients, thus reducing burdens on the biological end. 
However, both societal level costs of cancer and individual cost-sharing for cancer treatments continues 
to grow. Therefore, there is no current solution for aiding in mental health and improving quality of life 
for patients if cost-sharing at the individual level cannot be reduced. This study contributes to the 
current discussion of financial toxicity in cancer patients by examining which factors are associated with 
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financial difficulty, what cost-coping strategies patients use, and how financial difficulty and cost-coping 
strategies affect patients' quality of life. It will require further research to explain this dual threat but 
addressing financial burdens and distress is ultimately a piece of the puzzle for reduced mental health 
burdens and enhanced health-related quality of life.   
METHOD OF INVESTIGATION 
Study Design 
This was an observational, cross-sectional survey assessing patient-reported prescription 
medication adherence, financial coping strategies, subjective financial burden and self-reported health 
among patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). The survey 
instrument was developed, and pilot tested at Vanderbilt University and was self-administered through 
REDCap online. 
Participants 
Participants were enrolled via referral from Patient Power, an online community aimed at 
enabling and connecting cancer patients across the world to medical experts, and patient advocates 
through a variety of resources. The survey was first promoted on Patient Power’s social media platforms 
(Facebook, Instagram and Twitter) and patient newsletters on October 12, 2018. The survey was 
promoted a two weeks later via the same platforms, and closed November 4 (open for 23 days). Eligible 
patients were members of Patient Power who had one of three chronic blood cancers (chronic 
lymphocytic leukemia, chronic myeloid leukemia and multiple myeloma). The Vanderbilt University 
Institutional Review Board approved this study. Outlined in Figure 4, there were 342 total responses 
recorded, with 283 starting the survey, and 59 who opened but left incomplete or no responses. Of the 
283 completed surveys, 259 participants indicated that they had blood cancer, while 24 had another 
type of cancer. Since our interest is focused on participants with blood cancers, the other group was 
excluded Additionally, we excluded those with chronic myeloid leukemia because there was not a 
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sufficient number of responses (N=20) for analysis. Thus, we ended up with 239 survey responses for 
analyses (N=148 with chronic lymphocytic leukemia, N=91 with multiple myeloma).  
According to the American Cancer Society, the identified demographic risk factors for CLL 
average age at time of diagnosis is 70 years old and white. This is consistent with our cohort of patients, 
in that 98.7% identified as white, and 59.2% reported being over 65 years old (94.6% reported being 
over 55 years old). Risk factors identified for MM include being diagnosed over 60 years old, male and 
African American. This is consistent with our cohort, in that 86.9% report being over 55 years old. 
However, it is consistent in the fact that our cohort represented a minority of males (38.5%) and only 
6.6% African American for patients with multiple myeloma, which could produce potential bias in 
analysis.  
STATISTICAL ANALYSIS 
Descriptive statistics were used to summarize participants’ sociodemographic characteristics, 
disease and treatment characteristics, self-reported health, financial burden and use of cost-coping 
strategies. All analyses were conducted in collaboration with Dr. Stacie Dusetzina, associate professor in 
the department of Health Policy at Vanderbilt University. Bivariate and multivariate regression models 
were used to assess the association between patient sociodemographic characteristics and financial 
burden. I estimated the relationship between self-reported financial burden and health-related quality 
of life (PROMIS Global Mental & Physical Health Scores), and self-reported financial burden and cost-
related non-adherent behavior. Variables including gender, income, insurance type and use of 
prescription drug coverage were controlled for as possible covariates in adjusted analyses. A p value of 
<.05 in the final model was considered statistically significant. All models were calculated using SAS 
statistical software programming.  
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RESULTS 
Sociodemographic Characteristics 
The final sample included 239 eligible participants were analyzed for overall sociodemographic 
characteristics. Table 1 illustrates these characteristics stratified by disease type (CLL vs MM). The 
majority reported being diagnosed with chronic lymphocytic leukemia, were female, non-Hispanic 
white, 65-74 years old, and had a median income of $80,000-$99,999. Patients reported a median 
disease duration of between 2 to 5 years and over half (54.8%) report taking oral drugs as part of their 
current cancer-directed treatment. Most patients were either privately insured through their employer 
(46%) or had Medicare (54.1%). Overall, 96.6% reported having prescription drug coverage.  
Factors Associated with Financial Burdens 
Of respondents, 39.5% reported that having cancer caused financial hardship. Of those who 
reported financial hardship, One fifth report this being very difficult (Table 2). Additionally, almost one 
third of patients report significant or catastrophic financial burden as a result of having cancer.  This 
differed among patients based on their use of orally-administered anticancer drugs with those who 
reported taking oral drugs as part of their cancer treatment being 40% more likely to report any financial 
hardship.  
For our models, we recoded our outcome variable of subjective financial burden from the 5-
point Likert scale categories of 1 “not a financial burden at all”, 2 “minor financial burden”, 3 “moderate 
financial burden”, 4 “significant financial burden”, and 5 “catastrophic financial burden” to a binary 
variable of either 1 “financial burden” or 2 “no financial burden”. Patients who reported “not a financial 
burden at all” or “minor financial burden” were recoded as “no financial burden”. Patients who reported 
“moderate”, “significant” or “catastrophic” financial burdens were recoded as having financial burden.  
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We included gender, race, age, income, disease duration, and health insurance as possible 
covariates in our multivariate adjusted analysis. We did not include ethnicity or whether a patient had 
prescription drug coverage because there was little variability among the sample (95.4% non-Hispanic 
and 96.6% had prescription drug coverage). We recoded age from 6 categories into a binary variable as 
either younger than 65 years older 65 years and older to have even comparison categories. We recoded 
insurance from 6 categories to 3 new categories as either having Medicare, private insurance or 
unknown. The majority of respondents were over 65 and on Medicare, which is disproportionate to the 
general population – our sample reported 54.1% on Medicare, and general population in 2017 was 14% 
(Health Insurance Coverage 2017). This was to be expected, since the average disease onset of chronic 
blood cancers occurs after 65 years of age, which is when citizens become eligible for Medicare. Based 
on frequency data (found in Table 1) We combined disease duration categories of being diagnosed for 
“<6 months” and “7 months to <2 years” to just “<2 years”. 
Table 3 shows the results of both our bivariate and multivariate our regression analysis. In 
unadjusted analyses, female patients and patients under 65 years old were more likely to report 
financial burden than male patients and patients over 65 years old. Those who were diagnosed for 6-<10 
years reported greater financial burden than other disease duration groups. Regarding income, those 
with higher income ($80,000 - $100,000+) were less likely to experience financial burden. Lastly, 
patients with CLL were less likely to experience financial burdens than those with MM. In adjusted 
analyses, controlling for possible covariates, only oral drug use and disease duration were significantly 
associated with subjective financial burden (alpha of .05).  
Cost-Related Non-Adherence & Cost-Defray Techniques 
After collecting demographic data and subjective financial burden data, we asked participants if 
they were “currently taking oral prescription medications for treatment for cancer." Of the 239 
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participants who reported having either CLL or MM, 131 patients said “yes” they are currently taking 
orally prescribed drugs as part of their cancer treatment (n=66 for MM and n=65 for CLL). 131 
respondents that did respond yes to taking orally prescribed drugs were evaluated for the presence of 
cost-related non-adherence and other cost-defraying strategies.  These behaviors include “skipping 
medication doses”, “taking less medicine”, “delay filling a prescription”, “asking doctor for lower cost”, 
“buying prescription drugs from another country” and “using alternative therapies”.  Detailed in Table 4, 
Only 17.6% (n=23) of respondents who were prescribed oral drugs as part of treatment engaged in one 
or more cost-related non-adherent behavior. 73.3% (n=96) did not participate in any CRN behaviors, 
meaning they took their oral drugs used to treat cancer as prescribed by their physician. Additionally, 
cost-related non-adherent behaviors were broken down by either behavior related to cancer 
medication, behavior related to another medicine (not cancer related) or both. These findings are 
summarized in the graph below. 
While the cost-related non-adherence behaviors were less common among the cohort than has 
been observed in other studies, we found a much higher percentage of patients who reported using 
“cost-defraying” techniques to compensate for the high-cost of cancer drugs. These techniques include 
“obtaining samples from a doctor”, “cutting back on leisure activities”, “reducing spending on basics”, 
“using savings set aside for other purposes”, etc. In total, 63.4% (n=83) of the sample reported using at 
least one or more of these “cost-defraying” techniques.  
Financial Burden and Health-Related Quality of Life  
Our final outcome of interest was the association between health-related quality of life and 
financial burden. We were further interested in the distinction of whether this differed between 
patients who reported using oral anticancer drugs, and patients who did not take oral anticancer drugs 
as part of treatment. Table 5 summarizes Self-Reported Health using the PROMIS Global-10 Mental and 
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Physical Scale & Scoring and stratified by oral anticancer drug use. This is a publicly available and 
validated global health assessment tool that allows measurements of symptoms, functioning, and 
healthcare-related quality of life (HRQoL) for a wide variety of chronic diseases and conditions. The 
scoring system of the PROMIS Global-10 allows each of the individual items to be examined separately 
to provide specific information about perceptions of physical function, pain, fatigue, emotional distress, 
social health and general perceptions of health.   
Score interpretations are described in Figure 4 and help infer quantitative scores to qualitative 
ranges of health-related quality of life, ranging from “poor” to “excellent”, across a spectrum. The 
average mental health scores for the cohort (212 respondents, 20 did not report all scores for associated 
measure) were 46.5 (+/- 9.26) and the average physical health scores were 47.6 (+/- 9.59) which are 
both interpreted as “Good”. The difference for global mental health was only 1.2 points, and the 
difference for global physical health was only 0.9.   
We used a multivariate adjusted regression model to better understand the relationship 
between financial burden and its effect on both mental and physical health-related quality of life scores. 
We ran two different models – one using mental health PROMIS scores, and one using physical health 
PROMIS scores as our outcome variable. In our unadjusted analysis, seen in Table 6 we found a 6.62 
point decrease in mental-health scores and a 6.01 decrease in physical health scores. In Table 7 we 
controlled for possible covariates including age, gender, insurance, cancer type, disease duration and 
income, and still found a significant decrease of 4.86 in mental-health scores and 4.16 decrease in 
physical health scores.  
We were further interested in whether there was a difference in health-related quality of life 
between patients who used oral anticancer drugs, and patients who did not use oral anticancer drugs as 
part of treatment. In our multivariate adjusted regression model, controlling for the same possible co-
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variates previously mentioned, we did not find a significant difference between health-related quality of 
life scores and anticancer drug use. 
DISCUSSION 
1. What factors are associated with financial difficulty in cancer patients? 
 Previous research has detailed the burden of health care-related cost-sharing expense. 
Additionally, recent studies have specified the financial burdens associated with cancer treatments 
(Altice, 2016). However, this study is among the first to evaluate the subjective financial burden in a 
special cohort of patients who have a high proportion of oral anticancer drug users. These oral 
anticancer drugs or “TKI Inhibitors” are recent innovations to treatments, and although improving 
disease outcomes, their unaffordability and price tags of over $10,000 create subsequent financial 
difficulties.  
 A systematic review of financial toxicity among cancer populations reported the most common 
factors linked to financial toxicity were “being female, younger age, having a low income, receiving 
adjuvant therapies and having a recent diagnosis” and “high financial burden for cancer patients is in 
excess of that for persons not experiencing cancer” (Gordon, 2017). Consistent with recent evidence 
among other cancer patients, in our analysis we did find that patients who are female, younger, and 
lower income to have a greater risk for financial burdens. Additionally, patients with a disease duration 
of 6-<10 years report the highest level of financial burden, which could suggest the time when oral-
targeted treatments are usually administered or potential depletion of resources over time, but that 
cannot be validated by the data captured. Most treatment discourses, as mentioned before, are at a 
“watch and wait” stage if caught early on and patients do not begin treatment until the disease has 
progressed (American Cancer Society, 2018).  
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The impact of financial burdens can be debilitating to households, and identifying which patients 
are more at risk will help with any future intervention strategies. Although financial toxicity is a complex 
problem, a greater awareness and acknowledgement of burdens and associated risk factors can lead to 
solutions towards optimal patient outcomes by physicians, policymakers, patients, and families.  
2. How does this vary for people with cancer drugs, versus those who use other courses of treatment? 
 Due to the previously mentioned fact that CLL and MM are treated with a high proportion 
anticancer drugs compared to other types of cancers, we were interested in whether the hefty price tag 
of these drugs created a significant amount of financial difficulty, as compared to those who were not 
treated with anticancer drugs. 
 Cancer treatments are generally expensive, however anti-cancer drugs are more expensive than 
typical discourses of chemotherapy, surgery or “watch and wait” strategies (American Cancer Society, 
2018). This is consistent with our findings that patients who did take oral anticancer drugs reported 40% 
more financial difficulty than those who didn’t and a significant association between subjective financial 
burden and oral prescription drug use. This suggests a greater urgency in controlling prescription drug 
pricing, since it is an obvious predictor for subjective financial burdens. As research and development of 
oral anticancer drugs continue to progress, prices must be contained so patients have both accessible 
and affordable treatment options for better survivorship.  
3. Among cancer drug users, what are the cost coping strategies? 
Various cost-coping strategies to combat the high prices of drug treatments have been studied 
and classified into the 6 most common ways: skipping medication doses, taking less medicine, delaying 
filling a prescription, asking a doctor for a lower cost medication, buying prescription drugs from 
another country and using alternative therapies. Previous studies have evaluated how different diseases 
which are treated with oral medications, such as diabetes, hypertension, cardiovascular and other 
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chronic diseases (Qato, 2016). Due to the recent innovations in anticancer drugs, few studies have 
evaluated cost-related nonadherence among this patient population. 
The most common types of cost-related non-adherent behavior among our sample for cancer 
medications were delaying filling a prescription to save money and asking a doctor for a lower cost 
medication, although relatively low proportions of respondents engaged in these behaviors. More 
common strategies were not cost-related non-adherent behaviors, but rather “cost-defraying” 
strategies. 63.4% of patients reported using cost-defray strategies as compared to only 17.6% who 
participated in one or more CRN behavior. Although a complex issue, with various factors at play, our 
results indicate patients are more likely to follow treatments due to their life-saving capabilities but 
having to subsidize costs through other mechanisms. These most common mechanisms for defraying 
the cost-sharing of the cost of cancer care include cutting back on leisure activities, using savings and 
seeking pharmaceutical company assistance.  Possible factors associated with these patient decisions 
could be that patients are still choosing to fill their medications but engaging in other cost-savings 
strategies as a result. Furthermore, patients may be receiving assistance to manage prescription drug 
costs as many reported seeing such assistance. For example, national cancer societies such as the 
Leukemia and Lymphoma Society offer various co-pay assistance and patient financial assistance 
programs. These, along with other cost-related coping strategies could help limit the impact of out-of-
pocket costs patients pay for cancer drugs. 
 Approximately 17% of patients are using non-adherence strategies and the majority of these are 
not taking both their cancer medications or medications for another disease. To better understand what 
is occurring among these non-adherent groups of patients it may be useful to identify whether there are 
“clusters” of strategies that are occurring and for which patient groups. For example, are those in higher 
socioeconomic groups, who have savings set aside, more likely to participate in “using savings” and 
“cutting back on leisure activities”, compared to those in lower socioeconomic groups who may not 
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have savings set aside and are more likely to participate in strategies such as “seeking pharmaceutical 
assistance” and “reduce spending on basics”. A qualitative analysis to better understand the group of 
patients who use non-adherence strategies to reduce costs could also reveal a more robust insight into 
why patients make treatment decisions. It is vital to understand this subset of patients who use non-
adherence strategies because they could be at very high risk of negative health outcomes. 
4. How do cost-coping strategies vary between cancer and non-cancer drugs? 
 When asking about cost-related non-adherent behaviors, we wanted to ask about medications 
outside of cancer as well, to see if there was any variability in whether patients were adherent to cancer 
drugs as compared to non-cancer drugs. We assumed this sample would have possible comorbidities 
that required prescription medication due to age and risk factors of this patient population. A survey of 
2206 community-dwelling adults aged 62 to 85 years old found that 87% reported at least one 
prescription medication and 36% used five or more prescription medications (Qato, 2016). We found 
patients were more likely to skip medication doses, take less medicine, and buy prescription drugs from 
another country for non-cancer related medications. Alternatively, we found behaviors such as asking 
doctor for a lower cost medication and using alternative therapies equal or more common for cancer 
medications. Treatment discourses and disease type help illuminate why there may be differences 
between cancer and non-cancer drug adherence. Although we did not ask specific types of other 
medications and medical conditions were classified in the “other medications” category, chronic 
diseases and common medications among people over 65 years old would explain some of the 
differences observed. For example, prescription medications to manage chronic diseases such as 
hypertension are common among elderly individuals, and nonadherence to medications impacts more 
than two thirds of hypertensive individuals (Tibebu, 2017). Additionally, patients may not find the 
benefit of managing their blood pressure as vital and imperative to their health as managing a more 
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severe disease like cancer. Thus, they may be more willing to adhere to cancer treatments, and sacrifice 
spending money on other medications for non life-threatening diseases.  
5. How is health-related quality of life related to financial burden in cancer patients? 
We found a significant difference in both mental and physical health scores between patients who 
reported a financial burden versus those who did not. We found that patients reporting financial burden 
are more likely to have almost 5 points lower on mental health scores, and similarly over 4 points lower 
on physical health scores. Reviewing the spectrum of scores in Figure 4, this is important because 
subjective mental health is on approximately a 10-point scale, meaning for every 10-point increase in 
scores, category increases (i.e. from “fair” to “good” or “very good” to “excellent”). Additionally, a 
national dataset measuring healthy non-cancer adults found the average PROMIS physical health score 
to be 53.2 and average PROMIS mental health score to be 53.9 (Weaver, 2012). Thus, there is a clear 
distinction in non-cancer patient’s overall quality of life, as compared to our cohort of CLL and MM 
patients. This is critical information for practitioners to understand the burden of cancer and associated 
costs on overall quality of life. 
 If financial burden is associated with diminishing mental and physical health, there is evidence to 
suggest high financial toxicity among this patient population. As previously mentioned, financial toxicity 
has been compared to similar treatment toxicities such as nausea, vomiting, insomnia or depression that 
can lead to poorer patient outcomes at times of treatment delays or discontinuation (Gordon, 2017). 
Thus, physicians should be aware of patients who are at risk of non-biological factors such as financial 
toxicity, which could lead to poorer health outcomes.  
6. Is quality of life different for patients with and without anticancer oral drug use? 
 Although we found significance among overall reporting of financial burden and its relationship 
with health-related quality of life, we did not find a significant difference between mental and physical 
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health scores in patients who used orally prescribed drugs, versus those who did not. This could be due 
to a variety of factors, including the fact that more patients who take oral cancer drugs also report 
higher financial burden. Thus the “financial burden” category captures an accurate reflection of oral 
cancer drug users. Additionally, mental health and physical health have a large number of factors such 
as age, other co-morbidities, life events, and social networks that may have more important roles than 
oral drug use. Despite there not being a difference in oral anticancer drug users versus non-oral 
anticancer drug users, the findings that financial burden is significantly associated with both lower 
mental and physical health among chronic blood cancer patients, regardless of treatment type, should 
create a sense of urgency to seek ways to lower cost-sharing to improve health-related quality of life. 
LIMITATIONS 
 The findings from this study are subject to limitations and have several sources of bias that may 
impact the generalizability. First, we recruited patients specifically through Patient Power, a community 
for patient advocacy. Patients involved within these groups are more likely to be engaged in their cancer 
care since they are connected to resources with medical professionals and oncology specialists. 
Additionally, they may be more knowledgeable of the resources available to them to seek financial 
assistance to ease the burden of cost-sharing, since one of Patient Power’s mission is to provide 
financial, insurance and family resources. 
 Similarly, these patients were selected as a convenience sample and recruited through media 
platforms such as email, Facebook, Twitter and Instagram via an online survey. If a patient does not 
have access to a computer, phone or other device, they would not have been able to take the online 
survey.  This is reflected in our results, in that this patient sample tends to be of higher socioeconomic 
status (median income $80,000-$99,999). Additionally, patients report high private insurance rates (only 
2.0% uninsured) may be leaving out patients with lower socioeconomic status and uninsured patients. 
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Patients in these groups have been found by previous research to have even higher rates of financial 
burden and toxicity (Zafar, 2015) and tend to be more difficult to recruit by the low response rates of 
other survey studies focused on these populations. 
 Previous studies have looked at patients who are seeking financial assistance because they are 
unable to afford out of pocket copays or in patients with high uninsurance rates (Zafar, 2015). The 
uniqueness of this study is that it reveals essentially a “best-case scenario” of patients who are highly 
insured (96.6%) and of higher socioeconomic status (average household income greater than $80,000). 
This reveals that, despite having proper treatment coverage and financial flexibility to cover extraneous 
medical costs, we still see significant levels of financial burden in paying for cancer. Furthermore, If the 
“best case scenario” patients are unable to afford treatment, it is extremely concerning how these high 
costs will affect those in lower socioeconomic groups and those with less financial flexibility to pay for 
treatment. It would be expected that poorer, less well-connected patients are going to experience more 
hardship and likely even greater negative effects on health. 
 Another limitation of our study includes our measures associated with financial burden and 
cost-related non-adherence were all self-reported and subjective data, which were not validated. 
However, several previous studies evaluating similar patient populations have used the same 5-point 
Likert scale of “Not a financial burden at all” to “Catastrophic financial burden” as a tool to gage 
accurate levels of financial burden (Zafar, 2015) (Gordon, 107). Additionally, based on previous research, 
we used the indicator of cost-related non-adherence as participating in only one or more behaviors from 
a defined list. Further investigation into these behaviors could include evaluating those with 2 or less 
versus those with 3 or more, to have a better representation of true non-adherence to treatment, as 
well as potential for patients to write in other forms that could be considered “non-adherent” that were 
not on the list.  
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 Given the limitations, this study still provides novel insight and takes a deeper dive into the 
financial burdens experienced by a unique cohort of cancer patients. Different from previous studies, 
this study was able to study financial burdens and reduced quality of life within a well-insured and 
financially secure cohort of patients. Additionally, CLL and MM may be subjected to higher levels of 
financial burdens due to their unique treatment characteristics of taking orally-targeted drugs, as 
opposed to traditional cancer treatments such as chemotherapy or surgery.  
Suggestions for future research to offset some of these limitations include drawing from a larger 
sample size with universal data sets to be more generalizable to a larger population. Additionally, it 
would be interesting to compare financial toxicities across different cancer types, and other chronic 
diseases as well as capture other co-morbidities through electronic medical records.  
Future directions towards change could include the development of intervention strategies 
outside of cost-sharing subsidies (e.g. non-profits) to reduce prices for patients. It would also be 
interesting to take a deeper dive into patients who reported cost-related non-adherence behaviors to 
understand the key differences among these patients and those who do not skip medications, and what 
subsequent health risks non-adherent patients may be exposed to as a result of cost-cutting strategies.  
Additional directions include further acknowledgement and addressing of social determinants of health 
by practitioners as part of usual care, and lastly, policy directives and solutions to combat high 
prescription drug prices. 
CONCLUSION 
This study comes within a timely window for greater insight into a recent and growing issue in 
health policy. As healthcare costs are increasingly shifted to patients through premiums and out-of-
pocket costs, the ongoing surveillance of the multiple domains of financial hardship will be vital for 
cancer patients to navigate treatment options and survivorship. Additionally, increased knowledge 
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about financial coping behaviors such as cost-related non-adherence that patients use to manage cancer 
care will be critical in developing interventions to improve adherence to treatment and better 
survivorship. 
Patients with chronic blood cancers and who take oral anticancer drugs experience a 
considerable amount of subjective financial burden due to cost-sharing and other factors. Certain 
factors such as gender, age, income and disease duration are associated with higher financial burden, 
should be explored further to better understand how social determinants impact health and financial 
toxicity. These patients who experience financial burdens go to extreme lengths to manage paying for 
life-saving treatments such as depleting savings, borrowing money or reduce spending on basic needs. 
Additionally, some patients may not even take medications as prescribed due to high costs. This is 
extremely worrisome, in that if patients do not take medications as prescribed, they are at higher risks 
for poor health outcomes.  
Quality of life is also being diminished as patients must face battling cancer and financial distress 
congruently. Receiving a cancer diagnosis alone is subjective to higher rates of mental distress and lower 
rates of quality of life. The additional burden of financial barriers and high cost-sharing responsibilities 
to obtain proper care and treatments is likely to reduce health-related quality of life even further. 
Understanding how and among whom to best measure financial distress is critical to the design of future 
interventional studies towards improved health outcomes and quality of life among cancer patients. 
The results of this study come within a timely window where America is at a crossroads in 
determining the future of cancer treatment in our country. America is known for being the greatest 
innovator of scientific discoveries and leading cancer treatments. On the contrary, the U.S. also has the 
highest cost of healthcare spending per GDP, and the highest cost of pharmaceutical drugs. If these 
ground-breaking treatments are unaffordable, inaccessibility essentially makes innovation useless.  Will 
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legislators stand by as the exorbitant costs of cancer drugs continue to rise, or will they act to 
implement policy that will ease the financial burden of the millions of Americans battling cancer? 
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APPENDIX 
Figure 1: History of Prescription Drug Spending in the United States 
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Figure 2: Total Health Expenditures as Gross Domestic Product 
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Figure 3: High Cost of Patented Cancer Medicines in US 
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Figure 4: Patient Recruitment Flowchart 
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Figure 5: Cost-Related Non-Adherence 
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Figure 6: Cost Defray Strategies 
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Figure 7: PROMIS Global Mental & Physical Health T-Scores 
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NOTES 
PROMIS measures use Item Response Theory (IRT), which is “a family of statistical models that link 
individual questions to a presumed underlying trait or concept of global health represented by all items 
in the scale”. Responses were scored using the HealthMeasures Scoring Service. This method uses 
responses to each item for each participant and is more accurate than the use of raw score/scale score 
look up tables. The scoring service reports T-score values on independent respondents. The T-score 
rescales the raw sums core into a standardized score with a mean of 50 and standard deviation (SD) of 
10. Therefore, a person with a T-score of 60 is one SD above the mean. A higher PROMIS T-score on the 
Global Health scales is one standard deviation (more health) than the general population. The PROMIS 
Global scale produces two scores, a physical health score and a mental health score from 4 items each. 
PROMIS Global scores are interpreted based on the Hays et al. validated scale 
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Table 1. Demographic and Clinical Characteristics of Survey Respondents 
Demographics Total CLL MM Take Oral 
Anticancer 
Drugs 
Do Not Take 
Oral 
Anticancer 
Drugs 
Cancer Type 
(count/percentage) 
239 61.9% 38.1% 43.9% 72.5% 
Gender (%Female)  53.6%  48.7% 61.5% 51.9% 55.6% 
      
Race/Ethnicity      
Latino/Hispanic 4.6% 4.1% 5.6% 2.3% 7.5% 
Black 2.5% 0.0% 6.6% 3.1% 1.9% 
White 95% 98.7% 89.0% 93.9% 96.3% 
Other 2.1% 1.7% 3.4% 2.3% 0.9% 
Not Reported 0.8% 0.7% 1.1% 0.8% 0.9% 
      
Age       
26-44 1.3% 0.7% 2.2% 1.5% 0.9% 
45-54 7.1% 4.8% 11.0% 9.2% 4.7% 
55-64 36.6% 35.4% 38.5% 28.2% 46.7% 
65-74 44.5% 45.6% 42.9% 47.3% 41.1% 
75-84 9.7% 12.2% 5.5% 12.9% 5.6% 
85+ 0.8% 1.4% 0.0% 0.8% 0.9% 
      
Income       
<$20,000 - $39,999 25.0% 21.9% 30.0% 22.1% 28.6% 
$40,000 - $79,999 23.7% 23.3% 24.4% 21.4% 26.7% 
$80,000 - $100,000+ 49.2% 53.4% 42.2% 52.7% 44.8% 
Unreported/Don't Know 2.1% 1.4% 3.3% 3.8% 0% 
      
Disease Duration       
<6 months 3.5% 2.8% 4.6% 3.1% 4.0% 
7 months to <2 years 17.4% 11.3% 27.3% 18.3% 16.1% 
2 years to <5 years 31.7% 29.6% 35.2% 26.7% 38.4% 
6 years to <10 years 24.8% 26.1% 22.7% 27.5% 21.2% 
More than 10 years 22.6% 30.3% 10.2% 24.4% 20.2% 
      
      
Health Insurance      
Medicare 54.4% 55.0% 54.9% 61.1% 46.3% 
Private Insurance 40.6% 40.5% 40.7% 36.6% 45.4% 
Other 5.0% 5.4% 4.4% 2.3% 8.3% 
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Have Prescription Drug 
Coverage (%Yes) 
96.6% 94.4% 95.8% 93.8% 92.5% 
 
Take oral drugs as part of 
Cancer treatment  
54.8% 43.9% 72.5%   
Total sample size was 239 for demographic analysis  
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Table 2: Subjective Financial Burden by Anticancer Drug Use 
Financial Burden Total Take Oral 
Anticancer Drugs 
Do Not Take Oral 
Anticancer Drugs 
Caused family financial hardship? 
(%Yes) 
39.5% 44% 32.9% 
    
Level of difficulty    
Very difficult 19.8% 18.2% 23.1% 
Difficult 34.6% 32.7% 38.5% 
Less difficult 45.7% 49.1% 38.5% 
    
Level of financial burden    
Catastrophic 4.29% 4.8% 3.5% 
Significant 14.8% 16.0% 12.9% 
Moderate 24.3% 28.8% 17.6% 
Minor 29.1% 32.8% 23.5% 
Not at all 27.6% 17.6% 42.4% 
Total sample size for financial burden was 210 (29 respondents did not complete all required responses) 
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Table 3: Predicted Factors Associated with Subjective Financial Burden 
Predictors of Financial Burden  
Unadjusted P-value Adjusted P-value 
Use Oral Rx 1.195 (.90 - 1.58) 0.21 1.18 (.89 - 1.56) *0.04 
Don't use Oral Rx 
    
     
Under 65 1.34 (1.0 - 1.76) *0.03 1.29 (.95 - 1.75) 0.1 
65 and Older 
    
     
Female 1.15 (1.02 - 1.78) *0.04 1.13 (0.85 - 1.52) 0.38 
Male 
    
     
Medicare 1.04 (0.78 - 1.37) 0.8 1.13 (0.81 - 1.57) 0.48 
Private & Other 
    
     
CLL 0.65 (0.50 - 0.85) *0.00 0.77 (0.588 - 
1.03) 
0.08 
MM 
    
     
6 years - <10 years 1.67 (1.08 - 2.58) *0.02 1.64 (1.06 - 2.55) *0.03 
More than 10 years 
    
     
$80,000 - $100,000+ 0.71 (0.31 - 1.63) 0.42 0.72 (0.3 - 1.72) 0.46 
<$20,000 - $39,999 
    
$40,000 - $79,999 
    
Unreported 
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Table 4: Cost-Related Non-Adherent Behavior by Cancer Versus Non-Cancer Drugs 
Cost-related Non-adherence Total Cancer 
Med 
Other 
Med 
Both 
Skipped medication doses  6.1% 12.5% 25.0% 62.5% 
Took less medicine  9.9% 23.1% 38.5% 61.5% 
Delayed filling a prescription to save money 13.0% 5.9% 64.7% 29.4% 
Asked doctor for a lower cost medication 18.2% 29.2% 33.3% 37.5% 
Bought prescription drugs from another country 2.3% 0.0% 100.0% 0.0% 
Used alternative therapies 6.8% 33.3% 11.1% 55.6% 
 Total CLL MM 
CRN Indicator (Cancer Meds Only)  (23) 17.6% (11) 16.9% (12) 18.2% 
*131 patients are used for this sample who responded “Yes” to taking oral meds  
Cost-Defraying Strategies Total 
Obtain samples from a doctor 10.7% 
Cut back on leisure activities 32.1% 
Reduced spending on basics 26.7% 
Used savings set aside for other purposes 34.4% 
Borrowed money or used credit to pay for medications 19.9% 
Sought pharmaceutical company assistance 38.2% 
Shopped around at pharmacies to get med at lowest price 18.3% 
 
Cost Defray Indicator (83) 63.4% 
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Table 5: Health-Related Quality of Life by Anticancer Drug Use 
Self-Reported Health Total Take Oral 
Anticancer Drug 
Do Not Take Oral 
Anticancer Drugs 
General Health    
Excellent 4.7% 5.6% 3.5% 
Very Good 36.3% 36% 36.8% 
Good 35.4% 38.4% 31.0% 
Fair 20.3% 17.6% 24.1% 
Poor 3.3% 2.4% 4.6% 
    
Quality of life    
Excellent 10.9% 10.4% 11.5% 
Very Good 37.7% 38.4% 36.8% 
Good  28.3% 32.8% 21.8% 
Fair 19.8% 16.8% 24.1% 
Poor 3.3% 1.6% 5.8% 
    
Physical Health    
Excellent 3.3% 2.4% 4.6% 
Very Good 34.9% 37.6% 31.0% 
Good 32.6% 36.8% 26.4% 
Fair 25.0% 20.0% 32.2% 
Poor 4.3% 3.2% 5.8% 
    
Mental Health    
Excellent 16.1% 16.1% 16.1% 
Very Good 36.0% 39.5% 31.0% 
Good 26.1% 26.6% 25.3% 
Fair 19.9% 16.9% 24.1% 
Poor 1.9% 0.8% 3.45% 
    
Satisfaction with Social Activities    
Excellent 12.9% 12.8% 12.9% 
Very Good 35.7% 39.2% 30.6% 
Good 30.0% 31.2% 28.2% 
Fair 13.8% 11.2% 17.7% 
Poor 7.6% 5.6% 10.6% 
    
Carry out social activities and roles    
Excellent 14.6% 14.4% 14.9% 
Very Good 33.5% 36.0% 29.9% 
Good 25.0% 24.8% 25.3% 
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Fair 19.3% 20.0% 18.4% 
Poor 7.6% 4.8% 11.5% 
    
Carry out physical activities    
Completely  46.7% 47.2% 45.9% 
Mostly 27.1% 26.8% 27.6% 
Moderately 13.8% 14.6% 12.6% 
A little 12.4% 11.4% 13.8% 
    
 Bothered by emotional problems (anxious, depressed, irritable)   
Never 24.3% 26.6% 20.9% 
Rarely 23.8% 25.8% 20.9% 
Sometimes 35.7% 30.6% 43.0% 
Often 13.8% 14.5% 12.8% 
Always 2.4% 2.4% 2.3% 
    
Fatigue    
None 9.6% 9.8% 9.3% 
Mild 34.6% 36.9% 31.4% 
Moderate 41.4% 40.2% 43.0% 
Severe 10.1% 10.7% 9.3% 
Very Severe 4.3% 2.5% 6.9% 
    
PROMIS Scores    
PROMIS Physical Health 47.6 (+/- 9.59) 48.4 (+/- 8.87) 46.4 (+/- 10.47) 
PROMIS Mental Health 46.5 (+/- 9.26) 47.0 (+/- 8.9) 45.8 (+/- 9.72) 
Total sample size for PROMIS Score Analysis was 212 (27 respondents did not complete all required responses) 
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Table 6: Estimates of Financial Burdens Associated with Mental and Physical Health-Related Quality of 
Life, Unadjusted 
Parameter Estimate Standard 
Error 
95% Confidence Limits Z P-value 
Mental Health 
Financial Burden -6.6181 1.1881 [-8.9467, -4.2894] -5.57 <.0001 
Physical Health 
Financial Burden -6.0126 1.2725 [-8.5066, -3.5186] -4.73 <.0001 
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Table 7: Estimates of Financial Burdens Associated with Mental and Physical Health-Related Quality of 
Life Controlling for Covariates 
Parameter Estimate Standard 
Error 
95% Confidence Limits Z P-value 
Mental Health 
Financial Burden -4.8637 1.3403 -7.4908 -2.2367 -3.63 
Physical Health 
Financial Burden -4.1591 1.2578 -6.6243 -1.6940 -3.31 
 
 
